Canada Launches Six-Month Dosing of Trelstar for Prostate Cancer Patients
News
A new six-month dosing option (22.5 mg) dosage of Trelstar (triptorelin pamoate), a drug indicated for the palliative treatment of hormone dependent advanced prostate cancer, is now available in Canada. ... Read more